Clearside Biomedical
CLSD
CLSD was delisted on the 28th of November, 2025.
67 hedge funds and large institutions have $57.8M invested in Clearside Biomedical in 2021 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 22 increasing their positions, 14 reducing their positions, and 16 closing their positions.
68% more call options, than puts
Call options by funds: $2.48M | Put options by funds: $1.48M
57% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 14
19% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 16
3% more funds holding
Funds holding: 65 → 67 (+2)
0.08% more ownership
Funds ownership: 2.27% → 2.35% (+0.08%)
52% less capital invested
Capital invested by funds: $122M → $57.8M (-$63.7M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$6.98M |
| 2 |
Morgan Stanley
New York
|
+$3.45M |
| 3 |
BlackRock
New York
|
+$1.79M |
| 4 |
Renaissance Technologies
New York
|
+$1.42M |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$581K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$7.9M |
| 2 |
AIIC
AJU IB Investment Company
Seoul,
South Korea
|
-$1.76M |
| 3 |
RI
RTW Investments
New York
|
-$1.73M |
| 4 |
Invesco
Atlanta,
Georgia
|
-$1.66M |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
-$1.49M |
CLSD Hedge Fund Activity: Q4 2021 in Review
67 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q4 2021, worth a combined $57.8M — down 52% from $122M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new CLSD positions and 16 closed out — a net gain of 3 holders — while 22 added to existing stakes and 14 trimmed.
The largest buyer was Assenagon Asset Management, adding an estimated $6.98M. The largest seller was Acuta Capital Partners, exiting entirely with an estimated $7.9M sold.
- 67 institutional investors held Clearside Biomedical (CLSD) as of Q4 2021, up from 65 in Q3 2021.
- Funds reported $57.8M of Clearside Biomedical stock for Q4 2021, down 52% quarter-over-quarter.
- 19 funds opened new Clearside Biomedical positions in Q4 2021 and 16 closed out, a net change of +3 holders.
- The largest Clearside Biomedical buyer in Q4 2021 was Assenagon Asset Management, an estimated $6.98M added.
- The largest Clearside Biomedical seller in Q4 2021 was Acuta Capital Partners, an estimated $7.9M sold.
Based on aggregated 13F filings for Q4 2021.